Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 11 de 11
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Brain Behav ; 14(6): e3592, 2024 Jun.
Article de Anglais | MEDLINE | ID: mdl-38867460

RÉSUMÉ

PURPOSE: The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the studies that are currently accessible. METHOD: Preferred Reporting Items for Systematic Reviews and Meta-Analysis recommendations were followed. In order to find relevant studies on lecanemab, we carried out a thorough literature search utilizing the electronic databases MEDLINE via PubMed, Cochrane, Web of Science, EBSCOhost, and Scopus. Excluding any research using experimental animals, we looked at lecanemab's effectiveness and side effects in treating AD in human clinical trials. Three randomized controlled studies were included. FINDINGS: According to studies, lecanemab lessens clinical deterioration and reduces brain amyloid-beta plaques (difference,.45; 95% confidence interval,.67 to.23; p < .001). Participants who received lecanemab saw a greater frequency of amyloid-related imaging abnormalities (ARIA)-H (17.3% vs. 9.0%) and ARIA-E (12.6% vs. 1.7%), which is a significant adverse outcome. CONCLUSION: Lecanemab has been shown to have an impact on the two primary pathophysiologic indicators of AD (Aß and tau). There are still a lot of unresolved issues related to lecanemab. Future research on the effectiveness and safety of lecanemab is advised in order to determine that the advantages of this medication exceed the disadvantages.


Sujet(s)
Maladie d'Alzheimer , Anticorps monoclonaux humanisés , Humains , Maladie d'Alzheimer/traitement médicamenteux , Peptides bêta-amyloïdes/métabolisme , Encéphale/imagerie diagnostique , Plaque amyloïde , Anticorps monoclonaux humanisés/usage thérapeutique
3.
Cureus ; 15(9): e45998, 2023 Sep.
Article de Anglais | MEDLINE | ID: mdl-37900461

RÉSUMÉ

BACKGROUND: An infection with coronavirus disease 2019 (COVID-19) might show a wide range of symptoms. Many individuals still experience symptoms after a prolonged period of initial COVID-19. OBJECTIVES: The objective is to find out the prolonged consequences of COVID-19 with their associations. MATERIALS AND METHOD: Two hundred and eighty-six COVID-19 cases were the subject of this cross-sectional investigation, which was carried out in basic and secondary healthcare facilities in Bangladesh. COVID-19-positive participants with consent were interviewed in person about their sociodemographic traits, the nature of their COVID-19 infection, risk factors, present manifestations, etc. We carried out our statistical exploration by use of IBM SPSS Statistics for Windows, Version 22 (Released 2013; IBM Corp., Armonk, New York, United States). To evaluate differences, we utilized the chi-square (χ2) test as well as the unpaired t-test. Our significance threshold level was 0.05. RESULT: In this study, 18.5% of participants reported having post-COVID-19 symptoms. The four main symptom categories were anorexia (26.4%), myalgia (34.8%), fatigue (41.5%), and palpitations (25.5%). The majority of post-COVID-19 syndrome patients (e.g., 40.0%) were over 50 years old. Severe disease (81.8%) was more likely to develop post-COVID-19 illness. CONCLUSION: Fifty-three out of 286 participants (or 18.5%) reported having post-COVID-19 symptoms. The main symptom categories included fatigue, myalgia, anorexia, and palpitations. In order to determine the risk variables our data supports, additional investigation is required.

4.
Cureus ; 15(9): e46032, 2023 Sep.
Article de Anglais | MEDLINE | ID: mdl-37900494

RÉSUMÉ

Classical Hodgkin lymphoma (cHL) has achieved high cure rates as a result of recent advancements in treatment. However, recurring or relapsed illness still poses a therapeutic challenge. Immune checkpoint inhibitor pembrolizumab, which targets PD-1, is now being commonly used as part of immunotherapy for recurrent and relapsed cHL. We found eight appropriate articles through systematic search and conducted in-depth analysis to find insights into the effectiveness and safety profiles of pembrolizumab by analyzing clinical trial data in patients with recurrent and relapsed cHL. Analysis of the studies shows that response rates, progression-free survival, and patient-reported quality of life have all significantly improved. However, immune-related consequences are among the adverse outcomes. The necessity for continued study is highlighted by the variation in reported adverse events and follow-up times. Clinicians, researchers, and other healthcare professionals can use this study as a resource to provide knowledgeable and individualized patient care in cHL.

5.
Clin Case Rep ; 11(9): e7887, 2023 Sep.
Article de Anglais | MEDLINE | ID: mdl-37670816

RÉSUMÉ

Pituitary apoplexy is a rare entity, which is characterized by severe neurological, ophthalmological, and endocrinological complications, with acute adrenal crisis being a major concern. The diagnosis of pituitary apoplexy is challenging, particularly in cases where it coexists with bacterial meningitis, leading to a diagnostic dilemma and delay in treatment. We report a case of a 23-year-old female diagnosed with pituitary apoplexy with concurrent bacterial meningitis.

6.
Case Rep Nephrol ; 2023: 9355564, 2023.
Article de Anglais | MEDLINE | ID: mdl-37736112

RÉSUMÉ

While ureteropelvic junction (UPJ) obstruction is a well-recognized cause of unilateral or bilateral upper urinary tract dilatation in infants and the pediatric population, its occurrence in adults is less recognized. We present the case of a 68-year-old man who was being evaluated for chronic orthostatic hypotension and was incidentally found to have asymptomatic microscopic hematuria on urinalysis. A CT scan of the abdomen/pelvis, without and with contrast, revealed severe bilateral hydronephrosis due to UPJ obstruction. The patient has remained asymptomatic with preserved normal renal function over 7 years of follow-up.

7.
Cureus ; 15(8): e43149, 2023 Aug.
Article de Anglais | MEDLINE | ID: mdl-37692728

RÉSUMÉ

Electrolyte abnormalities are common in acute stroke patients and have a substantial impact on the course and prognosis of the disease. Electrolyte imbalances such as hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia, and phosphate abnormalities are frequently seen in this patient population. The incidence, root causes, and medical ramifications of electrolyte abnormalities in acute stroke patients are investigated in this comprehensive study. According to our research, hyponatremia is the most prevalent electrolyte imbalance. The most common reason for hyponatremia in stroke patients is the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Higher mortality rates, longer hospital admissions, and less favorable functional outcomes are all linked to hyponatremia. Acute stroke patients also typically experience hypokalemia, which affects the severity of the stroke and the recovery of functional abilities. The review furthermore emphasizes the incidence and clinical consequences of hypercalcemia, hypomagnesemia, hypophosphatemia, and hypocalcemia in patients with acute stroke. The results highlight the significance of early electrolyte imbalance detection and treatment in acute stroke patients. To better comprehend therapeutic approaches, evaluate their influence on stroke outcomes, and analyze prognostic implications, more research is required.

8.
Cureus ; 15(8): e44026, 2023 Aug.
Article de Anglais | MEDLINE | ID: mdl-37664355

RÉSUMÉ

The chemotherapeutic agent paclitaxel has significantly enhanced the treatment of various types of cancer. However, the quality of life of cancer patients is often impacted by the painful and dose-restrictive paclitaxel side effect known as paclitaxel-induced peripheral neuropathy (PIPN). A non-pharmacological method called cryotherapy has shown promise in alleviating PIPN-related symptoms. In this systematic review, we aimed to evaluate the safety and effectiveness of cryotherapy in preventing PIPN. The review analyzed four randomized controlled trials (RCTs) involving individuals treated with paclitaxel for breast and gynecological cancer. Cryotherapy showed success in lowering PIPN symptoms in several studies, as judged by various outcome measures, although the findings varied. The safety profile of cryotherapy was typically good, with minimal side effects. However, methodological variations and small sample sizes in the studies analyzed limit drawing definitive conclusions from them. To obtain conclusive evidence, studies with standardized techniques and larger sample sizes are required. Further research is necessary to understand cryotherapy's potential mechanisms and long-term effects. This review highlights the potential of cryotherapy in the management of PIPN, explains how it works, and suggests future research topics to improve its application.

9.
Data Brief ; 48: 109067, 2023 Jun.
Article de Anglais | MEDLINE | ID: mdl-37025508

RÉSUMÉ

In spite of being the fifth most spoken native language in the world, Bangla has barely received any attention in the domain of audio and speech recognition. This article represents a speech dataset of Bengali Abusive Words with some non-abusive wors which are very close to the abusive ones. In this work, a multipurpose dataset is presented to recognize automatic slang speech for Bangla language, which was prepared by collection, annotation, and refinement of data. It consists of 114 slang words and 43 non-slang words with 6100 audio clips. For the collection of slang words, 60 native speakers and for non-abusive words, 23 native speakers participated who were, speaking in various dialects from over 20 districts of Bangladesh, and 10 university students participated to evaluate this dataset including annotation and refinements. Researchers can use this dataset to develop an automatic Bengali Slang speech recognition system, and also it can be used as a new benchmark for creating speech recognition-based machine learning models. This dataset can be enrich-ed further, and some background noise in the dataset can be used to simulate a more real-world scenario if desired. Otherwise, these noises could also be removed.

10.
Cureus ; 14(8): e28367, 2022 Aug.
Article de Anglais | MEDLINE | ID: mdl-36168335

RÉSUMÉ

Diabetes mellitus (DM) and hepatic steatosis are two of the most common metabolic syndromes that affect the health of people globally. Empagliflozin (EMPA) is a promising drug of choice for the diabetic population. Recent studies have shown its beneficial effects not only on diabetic patients but also on patients suffering from cardiac, hepatic, neurological, or pancreatic anomalies. In this paper, we systematically searched electronic databases to compile literature that focuses on EMPA's effect on the prediabetic population, diabetic population, and hepatic lipid metabolism. We focus on the mechanism of EMPA, specifically by which it increases insulin sensitivity and fat browning and reduces fat accumulation. Overall, we hypothesized that by its effect on weight loss and reducing inflammatory markers and insulin resistance (IR), EMPA decreases the rate of prediabetes to diabetes conversion. We concluded that by improving hepatic and serum triglyceride, decreasing visceral fat, and its positive impact on hepatic steatosis, the drug improves hepatic lipid metabolism. Further research should be done on this matter.

11.
Data Brief ; 32: 106173, 2020 Oct.
Article de Anglais | MEDLINE | ID: mdl-32844105

RÉSUMÉ

The article represents coronavirus spread log history. The duration, coronavirus takes to spread from one country to another country, could be seen in this dataset and could predicted the same for future pandemics through this dataset. It is highly dependent on the cabalistic number of variables that is the main navel of these datasets. Information for this dataset is collected from trusted websites, local and international popular newspapers. This coronavirus dataset not only help to track the spreading route of coronavirus but also can be used for predicting the possible spreading route of similar future pandemics. This dataset consists of 186 countries' useful data related to COVID-19 pandemic from November 17, 2019, to May 16, 2020, with 8 unique variables that provide the information of the nature of the spread of COVID-19. The datasets mainly focus on two major fields, first one is First Case which consists of information of Date of First Case(s), Number of confirm Case(s) at First Day, Age of the patient(s) of First Case, Last Visited Country and the other one First Death information consist of Date of First Death and Age of the Patient who died first for every Country mentioning corresponding Continent.This dataset also can perform a bunch of predictions using Machine Learning applications, like -how fast the virus is spreading, affect rate, death rate, death rate and able to represent comparison between other pandemics. Using this dataset, any similar pandemic spreadness could be predicted earlier and necessary precaution measures could be taken.

SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...